

References

I-137

1. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. *N Engl J Med*. 2017;1331-44.
2. Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. *J Clin Oncol*. 2017;3529-3537.
3. Grigg A, Dyer MJS, Diaz MG, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. *Haematol Rep*. 2017;765-772.
4. Raedler LA. Gazyva (Obinutuzumab) approved as first-line treatment, with chemotherapy, for patients with follicular lymphoma. *Am Health Drug Benefits*. 2018;11:64-66.
5. Dhillon S. Obinutuzumab: A review in rituximab-refractory or -relapsed follicular lymphoma. *Targeted Oncol*. 2017;12(2):255-262.
6. Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN Study. *J Clin Oncol*. 2018;36(22):2259-2266.
7. Obinutuzumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated April 6, 2016.
8. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Obinutuzumab.
9. Micromedex DrugDex Compendium®. 2024. Obinutuzumab.
10. National Comprehensive Cancer Network (NCCN). Obinutuzumab. NCCN Drugs and Biologics Compendium®. 2024.
11. Gazyva® (obinutuzumab), for injection [package insert]. Genentech, Inc. South San Francisco, CA. Revised 7/2022.